Business
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first oral long-acting PTH peptide replacement tablet for hypoparathyroidism – Expanded 50/50 partnership with OPKO; intention to file IND in late 2026; data submitted to ENDO2026 EB618, the first oral OXM (dual GLP-1/Glucagon) tablet for metabolic and fibrotic condi
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio Ltd.","displaySize":"","headline":null,"caption":"Entera Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/f99611d3ae782150e893e9b0080a2af6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xxwg6MzoLJolPtGE.3oX7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/f99611d3ae782150e893e9b0080a2af6","width":150,"height":87},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/xxwg6MzoLJolPtGE.3oX7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/f99611d3ae782150e893e9b0080a2af6","width":150,"height":87}},"lazy":false},{"type":"text","content":"EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR ","length":221,"tagName":"p"},{"type":"text","content":"EB612, the first oral long-acting PTH peptide replacement tablet for hypoparathyroidism – Expanded 50/50 partnership with OPKO; intention to file IND in late 2026; data submitted to ENDO2026","length":190,"tagName":"p"},{"type":"text","content":"EB618, the first oral OXM (dual GLP-1/Glucagon) tablet for metabolic and fibrotic conditions – data submitted to ENDO2026","length":121,"tagName":"p"},{"type":"text","content":"Direct Investment led by BVF Partners L.P. to support EB613 pivotal study acceleration and working capital","length":106,"tagName":"p"},{"type":"text","content":"TEL AVIV, May 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.","length":264,"tagName":"p"},{"type":"text","content":"“The first quarter of 2026 solidified Entera’s position as the leading oral peptide therapeutics company. Our N-Tab® platform is developing arguably the richest pipeline of clinical and near-clinical first in class assets, and we are driven by our mission to develop transformative medicines and invest in therapeutic spaces that have been ignored and require urgent attention,” said Miranda Toledano, CEO of Entera.","length":416,"tagName":"p"},{"typ...